Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Professor Donnelly tries to understand the genetic basis of common human diseases. Information about the genetic variants can give us clues into the biology of the diseases. We can then use that information to develop new drugs, to find new drug targets and develop new therapies. Changes in clinical practice are already happening, and we expect genetics to play an important role in translational medicine over the next ten or twenty years.

Q: What are you trying to achieve in your research?

PD: My research tries to understand the genetic basis of common human diseases. We know that for many or most diseases, like arthritis, and schizophrenia, and diabetes, part of the story that makes some people more likely to develop those diseases (and some less likely), is to do with the DNA they inherit from their parents. That's part of the story. We know that part of the story is also lifestyle, environment, and diet and so on. My research is focussed on trying to learn, for a particular disease, which letters in our DNA, which parts of our DNA code are responsible for some people being more likely to get schizophrenia, which other parts are responsible for someone being more likely to get heart disease, and another person arthritis.

Q: What is the impact of knowing about the genetic basis of these diseases?

PD: There are two different sorts of impact. In some cases, if we find genetic variants which have big effects - and that's true for more rare diseases - then we can use them to identify people who are at high risk of those diseases. At the moment for common diseases, we're not very well placed to do that prediction, but on the other hand, knowing about the genetic variants can give us really important clues into the biology of the diseases. For most of the common diseases, we don't quite know what's causing them or triggering them, and if we can find changes in our DNA which are associated with the disease - if someone having a T in their code at this position is more likely to get heart disease than someone who has an A in that position, in their genetic code - then we can try and work out what the T does, and in contrast what the A does. That will potentially give us a clue about some biological aspect of the disease, what's happening within people to trigger the disease, and in turn we can try and use that information to understand the disease better and to develop new treatments, or new therapies.

Q: How do you carry out your studies and what are your challenges?

PD: Our studies involve collecting DNA from patients with the disease - who are happy to participate in the studies and have consented to do that - and comparing that with the DNA from healthy people. We will typically measure their DNA at a large number of positions, maybe half a million or a million, or possibly even read the entire DNA sequence, all three billion positions in the DNA sequence. We do that in a number of sick people, typically several thousand of them, and compare that with a number of healthy people. Then we're looking at the patterns, or we're looking for patterns which are more similar amongst the sick people than the healthy people, or the letters in the DNA code in particular positions, which are more common in the sick people than the healthy people. Part of my work is statistical, so it's developing methods to try and tease information out of these very large data sets.

Q: What are the most important lines of research that have developed in this field over the past 5 or 10 years?

PD: It's been a really exciting time - there's been an explosion in our understanding and knowledge of the genetic basis of common diseases. If we'd had this discussion six or seven years ago, across all of the common diseases that we suffer from, we knew maybe a handful of examples of genetic variants, which are common and affected people's risk of disease. While five or six years ago we knew five to ten examples, there are now over two thousand examples of documented genetic variants, which affect people's risk of diseases. It's been an extraordinarily exciting time in our ability to learn and understand more about the genetics of common diseases, and that shows no signs of slackening – there's more and more discovery on-going.

Q: Why does your line of research matter, why should we put money into it?

PD: I think studying the genetics of diseases gives us a particular way of understanding the disease. For most of the common diseases, in spite of (in many cases) decades of research, and in some cases hundreds of years of research, we know depressingly little about the key aspects of the disease: what's triggering it within people, what are the differences that cause some people to develop the disease and others not to, or in some cases people who develop a disease to progress well or not so well. Genetics gives us a whole new way of understanding that biology - it gives us new foot-holes into the biology of the diseases. Through understanding the genetics and learning what those genetic differences are doing, we have the chance to understand differences about the disease process. We can then use that information to develop new drugs, to find new drug targets and develop new ways of treating people.

Q: How does your research fit into Translational Medicine within the Department?

PD: I think genetics is a key part, and has a key role to play, in translation. Much of the research is at the basic science end, in terms of the fundamental underlying discoveries, but then it's really important for all of us (and certainly for my own work) to try and work out how we can move that in to the clinic - how we can make differences in medical treatment for people. I think genetics will have a huge effect in clinical medicine over the next ten or twenty years and we're already starting to see some changes. We're starting to see areas where knowledge of genetics - of the DNA variants that people carry, or even of their entire DNA sequences, in some cases knowledge of the genetics of the bacteria of the viruses that make it sick - can already be used by doctors to work out how to adapt treatments or give different treatments. I think genetics is starting to play an important role in translation, and over the next ten or twenty years it'll have a major impact on clinical medicine.

Peter Donnelly

Understanding which variations in our DNA affect susceptibility to diseases can provide new insights into the disease process and lead to new treatments. Professor Peter Donnelly leads large collaborative human genetic studies, and his group develops and applies statistical methods to extract maximal information from the large datasets generated by genomic studies.

More podcasts related to Genetics

Anna Gloyn: Genetics and Diabetes

Predictions suggest that by 2030, 366 million people worldwide will be affected by diabetes, a disease which already uses 10% of the NHS budget. Continued breakthroughs in the area of genetics related to different types of diabetes enable better diagnosis and treatment for patients and identify novel pathways that can be targeted for therapeutic interventions.

Erika Mancini: Chromatin Remodelling

Chromatin plays an important role in the regulation of gene expression. The movement of nucleosomes, packing and unpacking DNA, is governed by chromatin remodelling ATPases. Malfunctions in the regulation of chromatin structure often leads to complex multi-system diseases and cancer, notably leukemia.

Diabetes and Genomics by Mark McCarthy

Diabetes and obesity are both major challenges for global healthcare, with the social, health and economic costs over the next fifty years being in the ‘trillions’ of dollars. Genetics is one of the more important tools for developing a systematic understanding of the disease and how best to treat it in different patients.

Silvia Paracchini: Dyslexia and Genetics

Dyslexia is an impairment in learning to read that affects up to 10% of children; it can have profound effects on an individual life. Dyslexia has an important genetic component; candidate genes control important stages during foetal brain development. Understanding the biology of dyslexia could help us design more effective diagnostic criteria and treatment plans.

Claire Palles: Gastrointestinal cancers

The gastrointestinal track is responsible for more cancers than any other system. A condition called Barrett's oesophagus, characterised by a change in the cells lining the oesophagus, can lead to oesophageal adenocarcinoma. Only few people with Barrett's oesophagus will go on to develop cancer, and genome sequencing studies aim to identify genetic risk factors and therefore better target high-risk patients.

Antonio Velayos-Baeza: Rare neurological disorders

ChAc is a rare progressive neurological disorder caused by mutations in a very complex gene. A better understanding of the biology underlying this disease helps develop better diagnostic tools, and opens up the possibility of discovering targets for possible future treatments.

Zamin Iqbal: Computation and genetics

Resistance to drugs in bacteria can be aquired by swapping genes between individual bacteria. Computer programs developed by Dr Iqbal enable doctors to predict which antibiotics will be met with drug resistance, enabling the selection of the right drug. His work also enables the tracking of an infection from patient to patient, as well as the tracking of the spread of an infection within a hospital.

Gerton Lunter: The evolution of the genome

Computational and stastistical methods help us understand evolution as well as genetic disease. Looking at our genomes opens up clinical possibilities, for example in cancer, allowing more genes to be looked at - more quickly and more cheaply, wich can impact prognosis and treatment selection.

Catherine Green: DNA replication and Cancer

The process of DNA replication is complex, and mistakes can lead to genome instability. Surveillance systems are not always successful which results in mutations that have the potential to inactivate genes or change their activity. This can lead to cancer, and many chemotherapeutic drugs are designed to disrupt DNA replication. A better understanding of these mechanisms can help us develop new drugs with reduced side effects.

Christopher Yau: Big Data

Over the past decade, data-driven science has produced enormous sets of data. The convergence of statistics and computer science, in the field known as machine learning, provide the means to understand these large datasets. Ultimately, machine learning algorithms will be develop into clinical decision making support systems.

Translational Medicine

From Bench to Bedside

Ultimately, medical research must translate into improved treatments for patients. At the Nuffield Department of Medicine, our researchers collaborate to develop better health care, improved quality of life, and enhanced preventative measures for all patients. Our findings in the laboratory are translated into changes in clinical practice, from bench to bedside.